US Stock MarketDetailed Quotes
ITCI Intra-Cellular Therapies
- 86.590
- +0.160+0.19%
Close Nov 27 16:00 ET
- 86.590
- 0.0000.00%
Post 16:00 ET
9.18BMarket Cap-99528P/E (TTM)
86.780High85.130Low402.84KVolume85.570Open86.430Pre Close34.77MTurnover0.39%Turnover RatioLossP/E (Static)106.02MShares93.45052wk High8.02P/B8.98BFloat Cap58.92552wk Low--Dividend TTM103.74MShs Float93.450Historical High--Div YieldTTM1.91%Amplitude6.750Historical Low86.303Avg Price1Lot Size
Intra-Cellular Therapies Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -4.97%-26.53M | 101.47%542K | 43.20%-34.12M | 54.03%-124.2M | 94.74%-2.06M | 52.63%-25.27M | 61.18%-36.8M | 27.50%-60.07M | -4.10%-270.19M | 46.45%-39.19M |
| Net income from continuing operations | -8.52%-26.32M | 62.09%-16.22M | 65.39%-15.25M | 45.49%-139.67M | 35.09%-28.58M | 54.66%-24.26M | 50.60%-42.78M | 38.92%-44.05M | 9.81%-256.26M | 48.65%-44.03M |
| Depreciation and amortization | 2.22%138K | 4.88%129K | -1.49%132K | -19.51%528K | -4.90%136K | -20.59%135K | -28.49%123K | -21.64%134K | 23.08%656K | -2.05%143K |
| Other non cash items | -25.00%18K | 0.00%23K | 4.55%23K | 2.22%92K | 4.55%23K | 9.09%24K | 4.55%23K | -8.33%22K | -49.72%90K | -35.29%22K |
| Change In working capital | -20.37%-16M | 138.35%2.09M | -22.73%-30.52M | 49.12%-29.58M | 283.44%14.04M | -10.61%-13.29M | 76.79%-5.46M | -66.35%-24.87M | -815.10%-58.14M | -303.00%-7.66M |
| -Change in receivables | 101.58%106K | -0.96%-14.56M | -169.65%-17.14M | 29.44%-38.83M | 16.87%-11.35M | 53.95%-6.71M | -1.94%-14.42M | 49.86%-6.36M | -486.02%-55.03M | -323.81%-13.65M |
| -Change in inventory | -25.94%-1.37M | 86.15%-1.88M | 88.71%-499K | -64.96%-26.35M | -2,154.49%-7.28M | -176.56%-1.09M | 20.87%-13.55M | -8,138.18%-4.42M | -1,690.58%-15.97M | -247.49%-323K |
| -Change in prepaid assets | -15.66%-18.95M | -176.93%-7.8M | -127.34%-24M | 77.43%-4.46M | 1,261.62%12.35M | -166.43%-16.39M | 381.04%10.14M | -18.26%-10.56M | -76.20%-19.75M | -126.48%-1.06M |
| -Change in payables and accrued expense | -60.80%4.31M | 112.11%26.44M | 529.74%11.23M | 28.77%41.26M | 140.18%20.43M | 51.03%10.99M | 8.84%12.47M | -154.29%-2.61M | 109.26%32.04M | 202.42%8.5M |
| -Change in other current liabilities | 9.78%-83K | -26.67%-114K | 87.55%-115K | -310.28%-1.21M | 91.00%-101K | -4,500.00%-92K | -4.65%-90K | -151.79%-924K | 428.00%574K | -2,016.98%-1.12M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -4.97%-26.53M | 101.47%542K | 43.20%-34.12M | 54.03%-124.2M | 94.74%-2.06M | 52.63%-25.27M | 61.18%-36.8M | 27.50%-60.07M | -4.10%-270.19M | 46.45%-39.19M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -937.35%-209.2M | -91.80%7.77M | 198.28%16.18M | 182.21%105.54M | -5.65%47.42M | -119.00%-20.17M | 154.50%94.75M | 94.89%-16.46M | -145.79%-128.37M | -2.42%50.26M |
| Net PPE purchase and sale | -159.70%-696K | ---- | ---- | 65.42%-269K | -103.57%-1K | -129.06%-268K | ---- | ---- | -139.38%-778K | 2,900.00%28K |
| Net investment purchase and sale | -947.83%-208.51M | -91.75%7.82M | 198.28%16.18M | 182.93%105.81M | -5.60%47.42M | -118.72%-19.9M | 153.66%94.75M | 94.88%-16.46M | -145.46%-127.6M | -2.48%50.24M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -937.35%-209.2M | -91.80%7.77M | 198.28%16.18M | 182.21%105.54M | -5.65%47.42M | -119.00%-20.17M | 154.50%94.75M | 94.89%-16.46M | -145.79%-128.37M | -2.42%50.26M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 160.91%6.73M | 6,250.37%545.18M | 174.42%9.99M | -96.09%17.81M | 37.36%3M | -54.35%2.58M | 55.98%8.59M | -99.18%3.64M | 3,851.38%455.16M | -72.37%2.19M |
| Net common stock issuance | --0 | ---- | ---- | --0 | --0 | --0 | ---- | ---- | --433.72M | ---7K |
| Proceeds from stock option exercised by employees | 160.91%6.73M | -75.62%2.09M | 174.42%9.99M | -16.93%17.81M | 36.92%3M | -54.35%2.58M | 55.98%8.59M | -55.00%3.64M | 86.14%21.44M | -72.28%2.19M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 160.91%6.73M | 6,250.37%545.18M | 174.42%9.99M | -96.09%17.81M | 37.36%3M | -54.35%2.58M | 55.98%8.59M | -99.18%3.64M | 3,851.38%455.16M | -72.37%2.19M |
| Net cash flow | ||||||||||
| Beginning cash position | 382.65%695.06M | 82.72%141.57M | -0.56%149.52M | 60.36%150.37M | -26.22%101.15M | 83.13%144.01M | -40.72%77.48M | 60.36%150.37M | 52.60%93.77M | 27.51%137.11M |
| Current changes in cash | -434.33%-228.99M | 731.92%553.49M | 89.10%-7.95M | -101.50%-848K | 264.83%48.37M | -173.29%-42.86M | 227.80%66.53M | -297.37%-72.89M | 75.13%56.6M | 196.34%13.26M |
| End cash Position | 360.75%466.06M | 382.65%695.06M | 82.72%141.57M | -0.56%149.52M | -0.56%149.52M | -26.22%101.15M | 83.13%144.01M | -40.72%77.48M | 60.36%150.37M | 60.36%150.37M |
| Free cash flow | -6.59%-27.22M | 101.33%489K | 43.20%-34.12M | 54.06%-124.47M | 94.74%-2.06M | 52.24%-25.54M | 61.23%-36.8M | 27.99%-60.07M | -4.27%-270.96M | 46.48%-39.17M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data